MEFV and myeloid sarcoma: In accordance with Shinar et al.’s (2003) findings, Unal and colleagues found that the annual relapse rate was slightly higher among RR MS patients carrying MEFV mutations as compared to non-carrier RR MS patients, suggesting that MEFV mutations may confer a more progressive disease course.